[1. THEPOT S., BOEHRER S., SEKERES V. et al. (2014). A phase I/II trial of Erlotinib in higher risk myelodysplastic syndromes and acute myeloid leukemia after azacitidine failure. Leuk Res 38: 1430-143410.1016/j.leukres.2014.09.014]Search in Google Scholar
[2. RANKIN E. B., NARLA A., PARK J. K. et al. (2015). Biology of the bone marrow microenvironment and myelodysplastic syndromes. Mol Genet Metab 116: 24-2810.1016/j.ymgme.2015.07.004]Search in Google Scholar
[3. A DES L., ITZYKSON R., FENAUX P. (2014). Myelodysplastic syndrome. Lancet 383:2239-225210.1016/S0140-6736(13)61901-7]Search in Google Scholar
[4. CAZZOLA M., DELLA PORTA M. G, TRAVAGLINO E. et al. (2011). Classification and Prognostic Evaluation of Myelodysplastic Syndromes. Semin Oncol 38 (5): 627-63410.1053/j.seminoncol.2011.04.00721943669]Search in Google Scholar
[5. SWERDLOW S. H., CAMPO E., HARRIS N.L. et al. (2008). World Health Organization Classification of Tumours of Hematopoetic and Lymphoid Tissues. 4th Edition. Lyon: IARC Press 2008: 86-103.]Search in Google Scholar
[6. NIEMEYER CH. M., KRATZ CH. P. (2008). Paediatric myelodysplastic syndromes and juvenile myelomonocytic leukaemia: molecular classification and treatment options. Br J Haematol 140: 610-62410.1111/j.1365-2141.2007.06958.x18302710]Search in Google Scholar
[7. HASLE H., NIEMEYER CH. M. (2011). Advances in the prognostication and management of advanced MDS in children. Br J Haematol 154: 185–19510.1111/j.1365-2141.2011.08724.x21554264]Search in Google Scholar
[8. ORAZI A., CZADER B. M. (2009). Myelodysplastic Syndromes. Am J Clin Pathol 132: 290-30510.1309/AJCPRCXX4R0YHKWV19605823]Search in Google Scholar
[9. INAGAKI J., FUKANO R., KARAUCHI K. et al. (2015). Hemopoetic stem cell transplantation in children with refractory cytopenia of childhood: Single-center experience with high dose cytarabine containing myeloablative and aplastic anemia oriented reduced – intensity conditioning regimens. Biol Blood Marrow Transplant 21 (3): 565-56910.1016/j.bbmt.2014.12.00325498905]Search in Google Scholar
[10. HASEGAWA D., CHEN X., HIRABAYASHI S. et al. (2014). Clinical characteristics and treatement outcome in 65 cases with refractory cytopenia of childhood defined according to the WHO 2008 classification. Br J Haematol 166: 758-76610.1111/bjh.1295524894311]Search in Google Scholar
[11. NIEMEYER CH. M., BAUMANN I. (2011). Classification of childhood aplastic anemia and myelodysplastic syndromes. ASH Educational Book 2011 (1): 84-8910.1182/asheducation-2011.1.8422160017]Search in Google Scholar
[12. CHATTERJEE T., CHOUDHRY V. P. (2013). Childhood Myelodysplastic Syndrome. Indian J Pediatr 80 (9): 764-77110.1007/s12098-013-1130-823912822]Search in Google Scholar
[13. BASQUIRA A. L., PIZZI S., CORREAS A. G. et al. (2015). Allogenic hematopoetic stem cell transplantation in pediatric MDS: A multicenter experience from Argentina. Pediatr. Blood Cancer 62: 153-157]Search in Google Scholar
[14. HASLE H., NIEMEYER CH. M., CHESSELS J. M. et al. (2003). A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative disease. Leukemia 17: 277-28210.1038/sj.leu.240276512592323]Search in Google Scholar
[15. GLAUBACH T., ROBINSON L. J., COREY S. J. (2014). Pediatric Myelodysplastic Syndromes: They Do Exist! J Pediatr Hematol Oncol 36 (1): 1-710.1097/MPH.000000000000004624345881]Search in Google Scholar
[16. WU J. CHENG Y., ZHANG L. (2015). Comparison of immune manifestations between refractory cytopenia of childhood and aplastic anemia in children: A single-center retrospective study. Leuk Res 39 (12): 1347-1352]Search in Google Scholar
[17. JÄDERSTEN M., HELLSTRÖM-LINDBERG E. (2008). Myelodysplastic syndromes: biology and treatement. J Intern Med 265: 307-32810.1111/j.1365-2796.2008.02052.x19141095]Search in Google Scholar
[18. GREENBERG P. L. (2012). Molecular and genetic features of myelodysplastic syndrome. Int. Jnl. Lab. Hem. 34 : 215-222.]Search in Google Scholar
[19. WEINZIERL E. P., ARBER D. A. (2013). The differential diagnosis and bone marrow evaluation of new-onset pancytopenia. AM J Clin Pathol. 139: 9-2910.1309/AJCP50AEEYGREWUZ23270895]Search in Google Scholar
[20. VISCONTE V., LINDSLEY R. C., BERLYNE D. et al. (2015). Aplastic Anemia & MDS International Foundation (AA & MDS IF): Bone Marrow Failure Disease Scientific Symposium 2014. Leuk Res 39: 110-11310.1016/j.leukres.2014.11.00825435026]Search in Google Scholar
[21. GORDON-SMITH E. C. (2011). Blood and Bone Marrow Pathology (Second Edition). CHURCHILL LIVINGSTONE ELSEVIER, 2011, p. 213-224, ISBN 978-0-7020-3147-2]Search in Google Scholar
[22. KAO J. M., GREENBERG P. L. (2007). Myelodysplastic Syndromes: Impact of Recently Analyzed Variables for Modifying Current Classification Methods. Clinical Leukemia 1 (3) : 172-18210.3816/CLK.2007.n.005]Search in Google Scholar
[23. RADICH J. (2008). Solving the Mystery of Myelodysplasia. PLoS Med 5(2): e4010.1371/journal.pmed.0050040223589518271622]Search in Google Scholar
[24. INVERNIZZI R., FILOCCO A. (2010). Myelodysplastic syndrome: classification and prognostic systems. Oncol Rev 4: 25–3310.1007/s12156-009-0033-4]Search in Google Scholar
[25. MITTELMAN M., OSTER. H. S., HOFFMAN M. at al. (2010). The lower risk MDS patient at risk of rapid progression. Leuk Res 34: 1551-155510.1016/j.leukres.2010.05.02320573398]Search in Google Scholar
[26. AMERI A. A., CHERRY M., GARCIA-MANNERO G. et al. (2011). Standard Therapy for Patients With Myelodysplastic Syndromes. Clin Lymphoma Myeloma Leuk 11 (4): 303-31310.1016/j.clml.2011.06.00821816368]Search in Google Scholar
[27. SEKERES M. A (2013). The euphoria of hypomethylating agents in MDS and AML: Is it justified? Best Pract Res Clin Haematol. 26: 275-278]Search in Google Scholar
[28. PILO F., DI TUCCI A. A., DESSALVI P. et al. (2010). The evolving clinical scenario of myelodysplastic syndrome: The need for a complete and up to date upfront diagnostic assesment. Eur J Intern Med 21: 490–49510.1016/j.ejim.2010.09.00321111932]Search in Google Scholar
[29. MALCOVATI L., HELLSTRÖM-LINDBERG E., BOWEN D. et al. (2013). Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood 122 (17) : 2943-296410.1182/blood-2013-03-492884381117023980065]Search in Google Scholar
[30. VALENT P., ORAZIS A., BÜSCHE G. et al. (2010). Standards and Impact of Hematopathology in Myelodysplastic Syndromes (MDS). Oncotarget 1: 483 – 49610.18632/oncotarget.185]Search in Google Scholar
[31. HORNY H.-P., SOTLAR K., VALENT. P. (2007). Diagnostic value of histology and immunohistochemistry in myelodysplastic syndromes. Leuk Res 31: 1609–161610.1016/j.leukres.2007.05.01017604834]Search in Google Scholar
[32. HASSERIJAN R. P. (2015). Advances in the diagnosis and classification of myelodysplastic syndromes. Diagn Histopathol 21 (5): 203-21110.1016/j.mpdhp.2015.06.005]Search in Google Scholar
[33. MEERS S. (2014). The myelodysplastic syndromes: the area of understanding. Eur J Haematol 94: 379-39010.1111/ejh.1244325186093]Search in Google Scholar
[34. GIAGOUNIDIS A., HAASE D. (2013). Morphology, cytogenetics and classification of MDS. Best Pract Res Clin Haematol 26 : 337-35310.1016/j.beha.2013.09.00424507811]Search in Google Scholar
[35. BAUMANN I., FÜHRER M., BEHRENDT S. et al. (2012). Morphological differentiation of severe aplastic anemia from hypocellular refractory cytopenia of childhood: reproducibility of histopathological diagnostic criteria. Histopathology 61: 10-1710.1111/j.1365-2559.2011.04156.x22458667]Search in Google Scholar
[36. HAMA A., MANABE A., HASEGAWA D. et al. (2015). Comparison of clinical features between aplastic anemia and refractory cytopenia of childhood. Haematologica 100 (s2) : p2]Search in Google Scholar
[37. BAUMANN I. (2015). Morphologic diagnosis of RCC vs. SAA. Oral presentation-Keynote Lecture. 7th International Symposium on Myelodysplastic Syndromes, JMML and Bone Marrow Failure, Aarhus, Denmark, 1-3 October 2015]Search in Google Scholar
[38. FOUCAR K., VISWANATHA D.S., WILSON C. S. (2008). Non neoplastistic disorders of bone marrow, First series, Fascicle 6. Washington DC: ARP Press 2008: 84-89]Search in Google Scholar
[39. PARKER-WILLIAMS E. (2009). Investigation and management of anaemia. Medicine 37 (3): 137-14210.1016/j.mpmed.2009.01.005]Search in Google Scholar
[40. BIZZARO N., ANTICO A. (2014). Diagnosis and classification of pernicious anemia. Autoimmun Rev 13: 565-56810.1016/j.autrev.2014.01.04224424200]Search in Google Scholar
[41. BARONE A., LUCARELLI A., ONOFRILLO D. et al. (2015). Diagnosis and management of Acquired Aplastic Anemia in Childhood. Guidelines from the Marrow Failure Study Group of the Pediatric Heamato-Oncology Italian Association (AIEOP). Blood Cells Mol Dis 55 (1): 40-47]Search in Google Scholar
[42. GARCIA-MANERO G. (2015). Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification, and management. Am. J. Hematol. 90 (9): 832-84010.1002/ajh.2410226294090]Search in Google Scholar
[43. SMITH A. R., CHRISTIANSEN E. C., WAGNER J. E. et al. (2013). Early Hematopoetic Stem Cell Transplant Is Associated With Favorable Outcomes In Children With MDS. Pediatr. Blood Cancer 60: 705-710]Search in Google Scholar